Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima in Advanced/Metastatic Neuroendocrine Prostate Cancer
NCT04848337Phase 2Active, not recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in neuroendocrine prostate cancer (NEPC), sponsored by University of Michigan Rogel Cancer Center. Started May 2021; status: active, not recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT04848337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848337.